To evaluate for resistance to anti-EGFR therapy in colorectal cancer.
To evaluate for resistance to anti-EGFR therapy in colorectal cancer.
Highly specific in papillary thyroid carcinoma.
Highly specific in papillary thyroid carcinoma.
Rule out Lynch syndrome in people who show loss of MLH1 IHC staining on colorectal tissue.
Rule out papillary thyroid carcinoma.
Therapy selection and monitoring.